| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Chosa Oncology AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.084 |
| 52 Week High | SEK 0.096 |
| 52 Week Low | SEK 0.018 |
| Beta | 0 |
| 11 Month Change | 5.54% |
| 3 Month Change | 7.99% |
| 1 Year Change | 76.42% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 16.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| W5L | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 11.7% | -1.9% | -2.6% |
| 1Y | 76.4% | -17.3% | 3.9% |
Return vs Industry: W5L exceeded the German Biotechs industry which returned -17.3% over the past year.
Return vs Market: W5L exceeded the German Market which returned 3.9% over the past year.
Price Volatility
| W5L volatility | |
|---|---|
| W5L Average Weekly Movement | 13.2% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: W5L's share price has been volatile over the past 3 months.
Volatility Over Time: W5L's weekly volatility has decreased from 25% to 13% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2022 | 1 | Peter Jensen | www.chosaoncology.com |
Chosa Oncology AB develops oncology drugs for the treatment of cancer. The company was formerly known as Chosa ApS. Chosa Oncology AB incorporated in 2022 and is based in Lund, Sweden.
Chosa Oncology AB Fundamentals Summary
| W5L fundamental statistics | |
|---|---|
| Market cap | €3.29m |
| Earnings (TTM) | -€7.40m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs W5L overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| W5L income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 7.40m |
| Earnings | -SEK 7.40m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.10 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did W5L perform over the long term?
See historical performance and comparison